A new clinical trial involving 177Lu-DOTA-EB-TATE, a somatostatin-receptor-targeted compound, was listed on ClinicalTrials.gov as of August 3, 2026. The study, titled "177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer," is registered under identifier NCT06991738.
The trial is designated Phase 1/2 and its current status is listed as not yet recruiting. This indicates the study has been registered but has not yet begun enrolling participants.
The trial targets adult patients with metastatic Hurthle-cell thyroid cancer that does not respond to radioactive iodine treatment. No results, outcomes, or efficacy data have been posted for this trial at this time.
Somatostatin remains classified as an unapproved compound for research purposes. This trial update reflects only the registration status and does not indicate any findings about safety or effectiveness.
Further updates on recruitment status, enrollment progress, and any eventual results will depend on future postings to the trial registry. Readers interested in somatostatin can consult the compound overview for additional context.